The efficacy of T-VEC has been demonstrated in the pivotal phase 3, randomized, open-label OPTiM trial of T-VEC in adult patients with advanced melanoma, which showed significant improvement of the durable response rate over subcutaneous GM-CSF (16.3% vs. 2.1%; P < 0.001) (14). The gene discussed is CSF2; the disease is melanoma.